- Algernon Pharmaceuticals (CSE:AGN) will present its Phase 2a Ifenprodil cough data at the 9th American Cough Conference (ACC)
- Taking place June 9 to 10, 2023 in Reston, Virginia, the ACC is hailed as the world’s leading educational meeting for healthcare professionals involved in the research and management of patients with cough
- The team had reported that Ifenprodil, given three times daily, reduced geometric mean cough counts by 32 per cent at four weeks and 39.5 per cent at 12 weeks
- Algernon Pharmaceuticals Stocks (CSE:AGN) opened trading at $0.24 per share
Algernon Pharmaceuticals (CSE:AGN) will present its cough treatment data at the 9th American Cough Conference (ACC).
Taking place June 9 to 10, 2023 in Reston, Virginia, the ACC is hailed as the world’s leading educational meeting for healthcare professionals involved in the research and management of patients with cough.
The Vancouver-based company’s Vice President of Research and Operations, Christopher Bryan, PhD, will present “An update on NP-120 (ifenprodil): A subunit-selective NMDA receptor antagonist for the treatment of cough” during a thematic oral session on antitussive drug development programs. The focus of the talk will be on data from AGN-120-1, the company’s Phase 2a clinical trial in Idiopathic Pulmonary Fibrosis (IPF) and associated cough.
Ifenprodil selectively inhibits certain receptors found within the central and peripheral nervous system, including the area of the brain responsible for coordinating the cough reflex. It can diminish excitability of neurons and prevent the relaying of information along neuronal circuitry, including the cough reflex.
The company plans to give further details on its study. Previously, the team had reported that Ifenprodil, given three times daily in subjects with IPF and an associated cough, reduced geometric mean cough counts by 32 per cent at four weeks (p = 0.023) and 39.5 per cent at 12 weeks (p = 0.001) compared to baseline.
Algernon Pharmaceuticals Inc. (AGN) is a Canadian clinical-stage drug development company with active research programs for IPF, chronic cough, and chronic kidney disease. Its private subsidiary, Algernon NeuroScience, is advancing a psychedelic program investigating a proprietary form of psychedelic DMT for stroke and traumatic brain injury. For more details on the conference and to find out how to register, click here .
Algernon Pharmaceuticals (AGN) opened trading at $0.24 per share.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.